Diamond Hill Capital Management Inc. Increases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Diamond Hill Capital Management Inc. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,972,604 shares of the biopharmaceutical company’s stock after buying an additional 106,895 shares during the quarter. Diamond Hill Capital Management Inc. owned approximately 0.15% of Gilead Sciences worth $133,269,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its stake in Gilead Sciences by 1.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 5,129,197 shares of the biopharmaceutical company’s stock worth $320,822,000 after purchasing an additional 51,905 shares in the last quarter. Calamos Advisors LLC grew its holdings in shares of Gilead Sciences by 0.5% during the 1st quarter. Calamos Advisors LLC now owns 563,184 shares of the biopharmaceutical company’s stock valued at $36,613,000 after purchasing an additional 2,912 shares during the last quarter. Biltmore Family Office LLC grew its holdings in shares of Gilead Sciences by 3.8% during the 1st quarter. Biltmore Family Office LLC now owns 6,076 shares of the biopharmaceutical company’s stock valued at $395,000 after purchasing an additional 220 shares during the last quarter. PGGM Investments grew its holdings in shares of Gilead Sciences by 3.0% during the 1st quarter. PGGM Investments now owns 1,667,091 shares of the biopharmaceutical company’s stock valued at $108,378,000 after purchasing an additional 49,000 shares during the last quarter. Finally, Physicians Financial Services Inc. grew its holdings in shares of Gilead Sciences by 4.1% during the 1st quarter. Physicians Financial Services Inc. now owns 15,561 shares of the biopharmaceutical company’s stock valued at $1,012,000 after purchasing an additional 610 shares during the last quarter. 78.87% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:GILD opened at $64.30 on Wednesday. The stock’s 50 day simple moving average is $66.43. The company has a current ratio of 3.76, a quick ratio of 3.67 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $79.61. The firm has a market cap of $82.62 billion, a P/E ratio of 10.46, a PEG ratio of 3.10 and a beta of 1.16.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the consensus estimate of $1.68 by $0.14. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.54 billion. During the same period last year, the company earned $1.91 EPS. The firm’s revenue was down 2.8% compared to the same quarter last year. On average, equities analysts predict that Gilead Sciences, Inc. will post 6.65 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, September 12th. This represents a $2.52 annualized dividend and a yield of 3.92%. Gilead Sciences’s dividend payout ratio is presently 40.98%.

In other news, EVP Brett A. Pletcher sold 5,816 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total value of $399,850.00. Following the transaction, the executive vice president now owns 27,198 shares in the company, valued at approximately $1,869,862.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brett A. Pletcher sold 7,200 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total transaction of $468,504.00. Following the transaction, the executive vice president now owns 34,398 shares in the company, valued at approximately $2,238,277.86. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.

Several brokerages recently issued reports on GILD. Credit Suisse Group decreased their price target on shares of Gilead Sciences from $70.00 to $67.00 and set a “neutral” rating on the stock in a report on Wednesday, July 31st. Jefferies Financial Group set a $95.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Monday, July 15th. Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Thursday, May 2nd. Royal Bank of Canada raised shares of Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 price target on the stock in a report on Monday, July 29th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Monday, July 15th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $82.29.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: How Important is Technical Analysis of Stocks

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.